AngioDynamics Eyes Growth Despite Tariffs

Benzinga10-04

AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. Canaccord Genuity analysts, led by John Young,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572684611?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/03/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-10-04 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572684611","market":"nz","top_or_hot":-1,"title":"AngioDynamics Eyes Growth Despite Tariffs","media":"Benzinga","content":"<div>\n<p>AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.\nCanaccord Genuity analysts, led by John Young,...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48022434/angiodynamics-eyes-growth-despite-tariffs\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Eyes Growth Despite Tariffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Eyes Growth Despite Tariffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-04 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48022434/angiodynamics-eyes-growth-despite-tariffs><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.\nCanaccord Genuity analysts, led by John Young,...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48022434/angiodynamics-eyes-growth-despite-tariffs\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48022434/angiodynamics-eyes-growth-despite-tariffs","article_id":"2572684611","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/03/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48022434/angiodynamics-eyes-growth-despite-tariffs","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2572684611","pubTimestamp":1759510020,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"AngioDynamics, Inc.  posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.Canaccord Genuity analysts, led by John Young, reiterated their Buy rating on AngioDynamics and increased their price forecast to $18 from $17, citing growth across its portfolio and expectations for positive cash flow in fiscal 2026.First-quarter revenue rose 12.1% to $75.7 million, above consensus, led by a 26.2% jump in Med-Tech sales. Gross margin reached 55.3% versus 52.5% expected. Adjusted EPS of 10 cents loss was slightly below Canaccord’s forecast, but adjusted EBITDA of $2.2 million topped estimates.Management has raised fiscal year 2026 revenue guidance to $308 million to $313 million, reflecting stronger Med-Tech growth of 14% to 16%. The adjusted EBITDA is now expected to be between $6 million and $10 million, with positive cash flow anticipated for the year.Gross margin guidance was held steady at 53.5%-55.5% as the company faces head","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"尽管有关税，血管动力学仍着眼于增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1.5},"content_text":"AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.\nCanaccord Genuity analysts, led by John Young, reiterated their Buy rating on AngioDynamics and increased their price forecast to $18 from $17, citing growth across its portfolio and expectations for positive cash flow in fiscal 2026.\nFirst-quarter revenue rose 12.1% to $75.7 million, above consensus, led by a 26.2% jump in Med-Tech sales. Gross margin reached 55.3% versus 52.5% expected. Adjusted EPS of 10 cents loss was slightly below Canaccord’s forecast, but adjusted EBITDA of $2.2 million topped estimates.\nAlso Read: What’s Fueling The Momentum In AngioDynamics Stock?\nManagement has raised fiscal year 2026 revenue guidance to $308 million to $313 million, reflecting stronger Med-Tech growth of 14% to 16%. The adjusted EBITDA is now expected to be between $6 million and $10 million, with positive cash flow anticipated for the year.\nGross margin guidance was held steady at 53.5%-55.5% as the company faces headwinds from manufacturing transitions, raw material costs, and tariffs.\nMany of the Med-Device products manufactured in Costa Rica are subject to 15% tariffs. At the same time, some Med-Tech products with production in Italy and Poland is also subject to tariffs, resulting in an additional $4 million to $6 million in annual pressure.\nMechanical Thrombectomy revenue grew 41.2% year-over-year to $11.3 million, with both AngioVac and AlphaVac ahead of expectations. Canaccord anticipates sustained growth from cross-selling opportunities and an expanded sales force.\nAuryon delivered $16.5 million in revenue, up 20.1% year-over-year, beating estimates. The platform continues to expand in outpatient labs and hospitals, with international sales contributing after gaining CE mark approval.\nNanoKnife posted $6.4 million in revenue, up 26.7% year-over-year, with disposables sales well ahead of forecasts. Canaccord highlighted the quarter as particularly important, since NanoKnife has not yet seen any benefit from its CPT 1 code, which becomes effective January 1, 2026.\nAngioDynamics ended the quarter with $38.8 million in cash, no debt, and full access to a $25 million revolving credit facility. Management expects approximately $3 million of cash burn in the second quarter before turning cash flow positive in the second half.\nCanaccord now projects that AngioDynamics will post revenue of $310.9 million in fiscal year 2026 and $325.1 million in fiscal year 2027, compared with its prior estimates of $308.5 million and $326.6 million, respectively.\nThe analyst firm anticipates adjusted EPS losses of 33 cents for fiscal year 2026 and 4 cents for fiscal year 2027, compared to previous expectations of a 29-cent loss and a 1-cent profit.\nThe new $18 forecast is based on a sum-of-the-parts valuation, applying a 3.4x EV/sales multiple to the Med-Tech business and a 1.0x multiple to Med-Devices, based on fiscal year 2027 revenue estimates.\nPrice Action: ANGO shares were trading higher by 2.04% to $11.98 at last check Friday.\nRead Next:\nImage via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572684611","isCrawlerRequest":true}